Sign In
Buy VCEL
$34.74
+0.290 (+0.84%)
At Close: Jun 03, 2026
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
08:30am, Tuesday, 28'th Feb 2023
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
Vericel Corporation (VCEL) Q4 2022 Earnings Call Transcript
02:55pm, Thursday, 23'rd Feb 2023
Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Planning and Analysis and Investor Relations. Nick C
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
08:00am, Thursday, 09'th Feb 2023
CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
12:00am, Thursday, 12'th Jan 2023
Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
08:34am, Wednesday, 04'th Jan 2023
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Co
Vericel: Aggressive Growth In 2023
06:00am, Sunday, 01'st Jan 2023
Various ongoing fundamental improvements signal significant upsides. The recent NexoBrid approval foretells leaping sales growth in the coming quarters.
Vericel Corporation (VCEL) Q3 2022 Earnings Call Transcript
12:51pm, Wednesday, 09'th Nov 2022
Vericel Corporation (NASDAQ:VCEL ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Cola
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
08:30am, Wednesday, 26'th Oct 2022
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
08:30am, Thursday, 22'nd Sep 2022
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
08:30am, Tuesday, 06'th Sep 2022
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Compan
Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2022 Results - Earnings Call Transcript
02:57pm, Wednesday, 03'rd Aug 2022
Vericel Corporation (NASDAQ:VCEL ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colang
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
08:30am, Wednesday, 20'th Jul 2022
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel Corp (VCEL) CEO Dominick Colangelo on Q1 2022 Results - Earnings Call Transcript
05:31pm, Wednesday, 04'th May 2022
Vericel Corp (NASDAQ:VCEL ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Eric Burns - Executive Director, Financial Planning and Analysis & IR Dominick Colangelo - CEO,
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
10:32am, Wednesday, 04'th May 2022
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel: Poised For Growth
08:49am, Sunday, 17'th Apr 2022
The NexoBrid complete response letter sparked a market overreaction on Vericel Corporation stocks. Coupled with the 2021/2022 Biotech Bear market, Vericel shares are trading at a deep bargain to their
